Objective: The aim of this proposal is to engineer biocompatible nanoparticles that deliver short interfering RNA
(siRNA) to activated T cells (ATCs) for the downregulation of the Type 2 T helper cell (Th2) transcription factor GATA-3.
The nanoparticles have three components: a core filled with doxorubicin, a coating of short interfering RNA
(siRNA), and an outer layer that protects the particle from degradation in the bloodstream.
By blocking the production of BTC and ADAM10 with short interfering RNA
(siRNA), the researchers discovered they could protect these cell-cell tight junctions.
BAULCOMBE (2002): <<Two classes of short interfering RNA
in RNA silencing>>, EMBO Journal, vol.
This prediction was validated by experiments that showed that knocking down the expression of TRIB1 using short interfering RNA
(siRNA) led to cell cycle arrest.
The claims associated with the re-examinations include coverage for methods of enhancing silencing of a pharmaceutical composition containing short interfering RNA
(siRNA), micro RNA (miRNA), pre-miRNA or short hairpin RNA (shRNA) molecules.
Wei-Ping Min from the University of Western Ontario, the group demonstrated that nanoparticle administration of targeted short interfering RNA
(siRNA) was effective at protecting livers from damage caused by oxygen and nutrient deprivation.
In collaboration with Dr Wei-Ping Min from the University of Western Ontario, Medistem showed that the administering of nanoparticles targeting short interfering RNA
(siRNA) had positive effects in protecting livers from damage caused by oxygen and nutrient deprivation.
This volume contains 10 chapters that review recently reported short interfering RNA
(siRNA) design guidelines and clarifies the problems concerning the guidelines, as well as detailing an effective method for selecting siRNA target sequences from many possible candidate sequences using Bayes' theorem, the development of a durable RNAi therapy for cancer and viral infections, and the structure, application, and therapeutic challenges of siRNA.
Sirna's lead clinical development candidate, Sirna-027, is a chemically optimized, short interfering RNA
(siRNA) currently moving into Phase II development for the treatment of the wet-form of age related macular degeneration (AMD) as part of a broad collaboration with Allergan Inc.
RNAi is triggered by short interfering RNA
(siRNA) molecules that engage a group of cellular proteins, known as RISC (RNA induced silencing complex).
Gene Silencing, or RNA interference (RNAi) uses target-specific sequences of short interfering RNA
molecules (siRNA molecules) to knock-down, or "silence" targeted genes to infer their function.